GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gan & Lee Pharmaceuticals Co Ltd (SHSE:603087) » Definitions » Revenue

Gan & Lee Pharmaceuticals Co (SHSE:603087) Revenue : ¥2,947 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Gan & Lee Pharmaceuticals Co Revenue?

Gan & Lee Pharmaceuticals Co's revenue for the three months ended in Sep. 2024 was ¥930 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was ¥2,947 Mil. Gan & Lee Pharmaceuticals Co's Revenue per Share for the three months ended in Sep. 2024 was ¥1.51. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ¥5.00.

Warning Sign:

Gan & Lee Pharmaceuticals Co Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Gan & Lee Pharmaceuticals Co was 19.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -10.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -5.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 11 years, Gan & Lee Pharmaceuticals Co's highest 3-Year average Revenue per Share Growth Rate was 37.60% per year. The lowest was -19.00% per year. And the median was 14.40% per year.


Gan & Lee Pharmaceuticals Co Revenue Historical Data

The historical data trend for Gan & Lee Pharmaceuticals Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gan & Lee Pharmaceuticals Co Revenue Chart

Gan & Lee Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,895.06 3,361.88 3,612.04 1,712.27 2,608.04

Gan & Lee Pharmaceuticals Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 675.91 702.37 560.33 754.56 930.11

Competitive Comparison of Gan & Lee Pharmaceuticals Co's Revenue

For the Medical Instruments & Supplies subindustry, Gan & Lee Pharmaceuticals Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gan & Lee Pharmaceuticals Co's Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gan & Lee Pharmaceuticals Co's Revenue distribution charts can be found below:

* The bar in red indicates where Gan & Lee Pharmaceuticals Co's Revenue falls into.


;
;

Gan & Lee Pharmaceuticals Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,947 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gan & Lee Pharmaceuticals Co  (SHSE:603087) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Gan & Lee Pharmaceuticals Co Revenue Related Terms

Thank you for viewing the detailed overview of Gan & Lee Pharmaceuticals Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Gan & Lee Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 8, 1st Nanfeng West Road, Zhenxian Town, Tongzhou District, Beijing, CHN, 101102
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
Executives
Gan Zhong Ru Director

Gan & Lee Pharmaceuticals Co Headlines

No Headlines